Cargando…

Guiding model‐driven combination dose selection using multi‐objective synergy optimization

Despite the growing appreciation that the future of cancer treatment lies in combination therapies, finding the right drugs to combine and the optimal way to combine them remains a nontrivial task. Herein, we introduce the Multi‐Objective Optimization of Combination Synergy – Dose Selection (MOOCS‐D...

Descripción completa

Detalles Bibliográficos
Autores principales: Gevertz, Jana L., Kareva, Irina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681518/
https://www.ncbi.nlm.nih.gov/pubmed/37415306
http://dx.doi.org/10.1002/psp4.12997
_version_ 1785142553839927296
author Gevertz, Jana L.
Kareva, Irina
author_facet Gevertz, Jana L.
Kareva, Irina
author_sort Gevertz, Jana L.
collection PubMed
description Despite the growing appreciation that the future of cancer treatment lies in combination therapies, finding the right drugs to combine and the optimal way to combine them remains a nontrivial task. Herein, we introduce the Multi‐Objective Optimization of Combination Synergy – Dose Selection (MOOCS‐DS) method for using drug synergy as a tool for guiding dose selection for a combination of preselected compounds. This method decouples synergy of potency (SoP) and synergy of efficacy (SoE) and identifies Pareto optimal solutions in a multi‐objective synergy space. Using a toy combination therapy model, we explore properties of the MOOCS‐DS algorithm, including how optimal dose selection can be influenced by the metric used to define SoP and SoE. We also demonstrate the potential of our approach to guide dose and schedule selection using a model fit to preclinical data of the combination of the PD‐1 checkpoint inhibitor pembrolizumab and the anti‐angiogenic drug bevacizumab on two lung cancer cell lines. The identification of optimally synergistic combination doses has the potential to inform preclinical experimental design and improve the success rates of combination therapies. Jel classificationDose Finding in Oncology
format Online
Article
Text
id pubmed-10681518
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-106815182023-07-06 Guiding model‐driven combination dose selection using multi‐objective synergy optimization Gevertz, Jana L. Kareva, Irina CPT Pharmacometrics Syst Pharmacol Research Despite the growing appreciation that the future of cancer treatment lies in combination therapies, finding the right drugs to combine and the optimal way to combine them remains a nontrivial task. Herein, we introduce the Multi‐Objective Optimization of Combination Synergy – Dose Selection (MOOCS‐DS) method for using drug synergy as a tool for guiding dose selection for a combination of preselected compounds. This method decouples synergy of potency (SoP) and synergy of efficacy (SoE) and identifies Pareto optimal solutions in a multi‐objective synergy space. Using a toy combination therapy model, we explore properties of the MOOCS‐DS algorithm, including how optimal dose selection can be influenced by the metric used to define SoP and SoE. We also demonstrate the potential of our approach to guide dose and schedule selection using a model fit to preclinical data of the combination of the PD‐1 checkpoint inhibitor pembrolizumab and the anti‐angiogenic drug bevacizumab on two lung cancer cell lines. The identification of optimally synergistic combination doses has the potential to inform preclinical experimental design and improve the success rates of combination therapies. Jel classificationDose Finding in Oncology John Wiley and Sons Inc. 2023-07-06 /pmc/articles/PMC10681518/ /pubmed/37415306 http://dx.doi.org/10.1002/psp4.12997 Text en © 2023 The Authors. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research
Gevertz, Jana L.
Kareva, Irina
Guiding model‐driven combination dose selection using multi‐objective synergy optimization
title Guiding model‐driven combination dose selection using multi‐objective synergy optimization
title_full Guiding model‐driven combination dose selection using multi‐objective synergy optimization
title_fullStr Guiding model‐driven combination dose selection using multi‐objective synergy optimization
title_full_unstemmed Guiding model‐driven combination dose selection using multi‐objective synergy optimization
title_short Guiding model‐driven combination dose selection using multi‐objective synergy optimization
title_sort guiding model‐driven combination dose selection using multi‐objective synergy optimization
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681518/
https://www.ncbi.nlm.nih.gov/pubmed/37415306
http://dx.doi.org/10.1002/psp4.12997
work_keys_str_mv AT gevertzjanal guidingmodeldrivencombinationdoseselectionusingmultiobjectivesynergyoptimization
AT karevairina guidingmodeldrivencombinationdoseselectionusingmultiobjectivesynergyoptimization